Proactiveinvestors recommends
Additional Information
Market: TSX
Sector: Medical
EPIC: TH
Latest Price: 0.26  (0,00%)
52-week High: 1.90
52-week Low: 0.25
Market Cap: 15.86M
1 year chart
digital-look imported chart image
1 day chart
digital-look imported chart image
Theratechnologies
www.theratech.com

Theratechnologies Inc. (Theratechnologies) is a Canadian biopharmaceutical company that discovers and develops therapeutic products, which focused on peptides, for commercialization. The Company’s advanced compound, tesamorelin, is an analogue of the human growth hormone releasing factor.

Full Theratechnologies profile here
Pdf

Theratechnologies stock up after tesamorelin marketing process update

10th Oct 2012, 12:48 pm by Deborah Bacal
Theratechnologies' stock rose in Toronto on Wednesday after providing investors with an update on the marketing authorization progress of tesamorelin, a treatment for excess abdominal fat in HIV-infected patients. Theratechnologies' stock rose in Toronto on Wednesday after providing investors with an update on the marketing authorization progress of tesamorelin, a treatment for excess abdominal fat in HIV-infected patients.

Theratechnologies' (TSE:TH) (NASDAQ:THER) stock rose in Toronto on Wednesday after providing investors with an update on the marketing authorization progress of tesamorelin, a treatment for excess abdominal fat in HIV-infected patients. 

In Canada, the company said that, together with its commercial partner in the country, Actelion Pharmaceuticals, it responded to additional questions Health Canada had regarding the long-term safety of the drug. 

Health Canada is now reviewing the new drug submission, and Theratechnologies expects to receive a decision within 150 days.

In Latin America, the company said that it and its partner in the region, Sanofi, have been able to address "all technical deficiencies" identified by Brazil's National Health Surveillance Agency, following an audit of its Montreal-based third party manufacturing site in June. 

The corrective measures proposed by the regulatory body, and agreed to by the third-party manufacturer, are now being implemented, the drug maker said. 

The company noted that the evaluation of the Brazilian marketing application is a separate process, which is being conducted in parallel with the manufacturing assessment.

In Venezuela, the company was advised that its filing made in June of this year was incomplete for technical reasons, and it expects Sanofi to resubmit in "due course". The review process here, will, as a result, start fresh. 

Meanwhile, in Europe, following the withdrawal of the marketing authorization application  for the drug in the summer, Theratechnologies says it continues to "actively assess and evaluate" various options to resubmit an application in this region. 

This process is ongoing, with no firm timelines available as of this date, it added. Any new submission will be covered by a 10-year exclusivity period if approved.

The specialty pharmaceutical company discovers and develops therapeutic peptide products, with an emphasis on growth-hormone releasing factor peptides. Shares in the company in Toronto rose more than 4 per cent to 50 cents late morning Wednesday. 

No investment advice


Proactive Investors North America Inc, trades as "Proactiveinvestors USA & Canada".


You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.


You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.


From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.


You understand that we may be providing advertising and/or marketing services to companies mentioned on the site. A full list of companies that are paying for services from us, or our affiliated companies in the UK and Australia can be viewed here